

This listing of claims will replace all prior versions an listings of the claims in the application:

Listing of Claims:

- 5 1. (Original) Pharmaceutical compositions, comprising two or more substances of the group of  $\alpha$ -lipoic acid and its salts and isomers, ambroxol and its salts and prodrugs and inhibitors of the angiotensin-converting enzyme (ACE), optionally together with usual pharmaceutically acceptable  
10 carriers, additives and adjuvants.
2. (Original) Pharmaceutical compositions according to claim 1, comprising a combination of  $\alpha$ -lipoic acid or its salts or its isomers and of ambroxol or its salts or its prodrugs.
- 15 3. (Original) Pharmaceutical compositions according to claim 1, comprising a combination of  $\alpha$ -lipoic acid or its salts or its isomers and of at least one inhibitor of the angiotensin-converting enzyme.
- 20 4. (Original) Pharmaceutical compositions according to claim 1, comprising a combination of ambroxol or its salts or its prodrugs and of at least one inhibitor of the angiotensin-converting enzyme.
- 25 5. (Currently amended) Pharmaceutical compositions according to ~~any of the claims 1 to 4~~, comprising a combination of  $\alpha$ -lipoic acid or its salts or its isomers and of ambroxol or its salts or its prodrugs and of at least one inhibitor of the angiotensin-converting enzyme.

6. (Currently amended) Pharmaceutical compositions according to ~~any of the claims 1 to 5~~, additionally comprising one or several known carriers, adjuvants and/or additives.
- 5 7. (Currently amended) Pharmaceutical compositions according to ~~any of the claims 1 to 6~~, comprising  $\alpha$ -lipoic acid or its salts or its isomers in amounts in the range of from 30 to 1,200 mg/day, preferably in the range of from 200 to 600 mg/day, 10 and/or ambroxol or its salts or its prodrugs in amounts in the range of from 7.5 to 90 mg/day, preferably in the range of from 60 to 75 mg/day, and/or at least one inhibitor of the angiotensin-converting enzyme in amounts in the range of from 1 15 to 50 mg/day, preferably in the range of from 5 to 20 mg/day.
8. (Currently amended) Pharmaceutical compositions according to ~~any of the claims 1, to 7~~ for an oral, buccal, pulmonary, nasal, transdermal, intravenous, 20 subcutaneous, intracutaneous, intramuscular, rectal, vaginal and intrathecal administration.
9. (Currently amended) Pharmaceutical compositions according to ~~any of the claims 1, to 7~~ in the form of tablets, powders, granulates, capsules, 25 solutions, emulsions, suspensions, aerosols, transdermal application systems, suppositories and administration forms having a retarded release of single or all effective agents.

10. (Currently amended) ~~Use of~~ A method comprising  
utilizing the pharmaceutical compositions according  
to ~~one or several of the claims 1, to 9~~ for a  
prevention and a therapy of neurodegenerative  
diseases.
11. (Currently amended) ~~Use~~ A method according to  
claim 10 for a prevention and a therapy of the  
diseases ischemic or hemorrhagic stroke,  
amyotrophic lateral sclerosis, Alzheimer's disease,  
Parkinson's disease, Huntington's disease,  
multiple sclerosis, neurodegeneration of aged  
people, dementia, cranial cerebral trauma, and  
Autosomal Dominant Neurohypophyseal Diabetes  
Insipidus.
12. (Currently amended) ~~Use~~ A method according to  
claim 10 for a prevention and a therapy of cerebral  
ischemia resulting from cardial and cardiovascular  
insults.
13. (New) Pharmaceutical compositions according to  
claim 2, comprising a combination of  $\alpha$ -lipoic acid  
or its salts or its isomers and of ambroxol or its  
salts or its prodrugs and of at least one inhibitor  
of the angiotensin-converting enzyme.
14. (New) Pharmaceutical compositions according to  
claim 3, comprising a combination of  $\alpha$ -lipoic acid  
or its salts or its isomers and of ambroxol or its  
salts or its prodrugs and of at least one inhibitor  
of the angiotensin-converting enzyme.

15. (New) Pharmaceutical compositions according to claim 4, comprising a combination of  $\alpha$ -lipoic acid or its salts or its isomers and of ambroxol or its salts or its prodrugs and of at least one inhibitor of the angiotensin-converting enzyme.
16. (New) Pharmaceutical compositions according to claim 2, additionally comprising one or several known carriers, adjuvants and/or additives.
17. (New) Pharmaceutical compositions according to claim 3, additionally comprising one or several known carriers, adjuvants and/or additives.
18. (New) Pharmaceutical compositions according to claim 4, additionally comprising one or several known carriers, adjuvants and/or additives.
19. (New) Pharmaceutical compositions according to claim 5, additionally comprising one or several known carriers, adjuvants and/or additives.
20. (New) Pharmaceutical compositions according to claim 2, comprising  $\alpha$ -lipoic acid or its salts or its isomers in amounts in the range of from 30 to 1,200 mg/day, preferably in the range of from 200 to 600 mg/day, and/or ambroxol or its salts or its prodrugs in amounts in the range of from 7.5 to 90 mg/day, preferably in the range of from 60 to 75 mg/day, and/or at least one inhibitor of the angiotensin-converting enzyme in amounts in the range of from 1 to 50 mg/day, preferably in the range of from 5 to 20 mg/day.

21. (New) Pharmaceutical compositions according to claim 3, comprising  $\alpha$ -lipoic acid or its salts or its isomers in amounts in the range of from 30 to 1,200 mg/day, preferably in the range of from 200 to 600 mg/day, and/or ambroxol or its salts or its prodrugs in amounts in the range of from 7.5 to 90 mg/day, preferably in the range of from 60 to 75 mg/day, and/or at least one inhibitor of the angiotensin-converting enzyme in amounts in the range of from 1 to 50 mg/day, preferably in the range of from 5 to 20 mg/day.
22. (New) Pharmaceutical compositions according to claim 4, comprising  $\alpha$ -lipoic acid or its salts or its isomers in amounts in the range of from 30 to 1,200 mg/day, preferably in the range of from 200 to 600 mg/day, and/or ambroxol or its salts or its prodrugs in amounts in the range of from 7.5 to 90 mg/day, preferably in the range of from 60 to 75 mg/day, and/or at least one inhibitor of the angiotensin-converting enzyme in amounts in the range of from 1 to 50 mg/day, preferably in the range of from 5 to 20 mg/day.
23. (New) Pharmaceutical compositions according to claim 5, comprising  $\alpha$ -lipoic acid or its salts or its isomers in amounts in the range of from 30 to 1,200 mg/day, preferably in the range of from 200 to 600 mg/day, and/or ambroxol or its salts or its prodrugs in amounts in the range of from 7.5 to 90 mg/day, preferably in the range of from 60 to 75 mg/day, and/or at least one inhibitor of the

angiotensin-converting enzyme in amounts in the range of from 1 to 50 mg/day, preferably in the range of from 5 to 20 mg/day.

- 5           24. (New) Pharmaceutical compositions according to  
claim 6, comprising  $\alpha$ -lipoic acid or its salts or  
its isomers in amounts in the range of from 30 to  
1,200 mg/day, preferably in the range of from 200  
to 600 mg/day, and/or ambroxol or its salts or its  
10           prodrugs in amounts in the range of from 7.5 to 90  
mg/day, preferably in the range of from 60 to 75  
mg/day, and/or at least one inhibitor of the  
angiotensin-converting enzyme in amounts in the  
range of from 1 to 50 mg/day, preferably in the  
range of from 5 to 20 mg/day.
- 15           25. (New) Pharmaceutical compositions according to  
claim 2, for an oral, buccal, pulmonal, nasal,  
transdermal, intravenous, subcutaneous,  
intracutaneous, intramuscular, rectal, vaginal and  
intrathecal administration.
- 20           26. (New) Pharmaceutical compositions according to  
claim 3, for an oral, buccal, pulmonal, nasal,  
transdermal, intravenous, subcutaneous,  
intracutaneous, intramuscular, rectal, vaginal and  
intrathecal administration.
- 25           27. (New) Pharmaceutical compositions according to  
claim 4, for an oral, buccal, pulmonal, nasal,  
transdermal, intravenous, subcutaneous,  
intracutaneous, intramuscular, rectal, vaginal and  
intrathecal administration.

28. (New) Pharmaceutical compositions according to  
claim 5, for an oral, buccal, pulmonal, nasal,  
transdermal, intravenous, subcutaneous,  
intracutaneous, intramuscular, rectal, vaginal and  
intrathecal administration.  
5
29. (New) Pharmaceutical compositions according to  
claim 6, for an oral, buccal, pulmonal, nasal,  
transdermal, intravenous, subcutaneous,  
intracutaneous, intramuscular, rectal, vaginal and  
intrathecal administration.  
10
30. (New) Pharmaceutical compositions according to  
claim 7, for an oral, buccal, pulmonal, nasal,  
transdermal, intravenous, subcutaneous,  
intracutaneous, intramuscular, rectal, vaginal and  
intrathecal administration.  
15
31. (New) Pharmaceutical compositions according to  
claim 2, in the form of tablets, powders,  
granulates, capsules, solutions, emulsions,  
suspensions, aerosols, transdermal application  
systems, suppositories and administration forms  
having a retarded release of single or all  
effective agents.  
20
32. (New) Pharmaceutical compositions according to  
claim 3, in the form of tablets, powders,  
granulates, capsules, solutions, emulsions,  
suspensions, aerosols, transdermal application  
systems, suppositories and administration forms  
having a retarded release of single or all  
effective agents.  
25

33. (New) Pharmaceutical compositions according to claim 4, in the form of tablets, powders, granulates, capsules, solutions, emulsions, suspensions, aerosols, transdermal application systems, suppositories and administration forms having a retarded release of single or all effective agents.
34. (New) Pharmaceutical compositions according to claim 5, in the form of tablets, powders, granulates, capsules, solutions, emulsions, suspensions, aerosols, transdermal application systems, suppositories and administration forms having a retarded release of single or all effective agents.
35. (New) Pharmaceutical compositions according to claim 6, in the form of tablets, powders, granulates, capsules, solutions, emulsions, suspensions, aerosols, transdermal application systems, suppositories and administration forms having a retarded release of single or all effective agents.
36. (New) Pharmaceutical compositions according to claim 7, in the form of tablets, powders, granulates, capsules, solutions, emulsions, suspensions, aerosols, transdermal application systems, suppositories and administration forms having a retarded release of single or all effective agents.




37. (New) A method comprising utilizing the pharmaceutical compositions according to claim 2 for a prevention and a therapy of neurodegenerative diseases.
- 5 38. (New) A method comprising utilizing the pharmaceutical compositions according to claim 3 for a prevention and a therapy of neurodegenerative diseases.
- 10 39. (New) A method comprising utilizing the pharmaceutical compositions according to claim 4 for a prevention and a therapy of neurodegenerative diseases.
- 15 40. (New) A method comprising utilizing the pharmaceutical compositions according to claim 5 for a prevention and a therapy of neurodegenerative diseases.
- 20 41. (New) A method comprising utilizing the pharmaceutical compositions according to claim 6 for a prevention and a therapy of neurodegenerative diseases.
42. (New) A method comprising utilizing the pharmaceutical compositions according to claim 7 for a prevention and a therapy of neurodegenerative diseases.
- 25 43. (New) A method comprising utilizing the pharmaceutical compositions according to claim 8 for a prevention and a therapy of neurodegenerative diseases.

44. (New) A method comprising utilizing the  
pharmaceutical compositions according to claim 9  
for a prevention and a therapy of neurodegenerative  
diseases.

5

Respectfully submitted,

10

By:   
Martin G. Linihan  
Reg. No. 24,926

15

Hodgson Russ LLP  
One M&T Plaza, Suite 2000  
Buffalo, New York 14203  
Telephone: 716-848-1367  
Dated: January 26, 2004